دورية أكاديمية
[Treatment and prognosis].
| العنوان: | [Treatment and prognosis]. |
|---|---|
| عنوان ترانسليتريتد: | Tratamiento y pronóstico. |
| المؤلفون: | Catoggio LJ; Sección de Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Fundacion Dr. Pedro M. Catoggio para el Progreso de la Reumatología, Buenos Aires, Argentina; Instituto Universitario Escuela de Medicina Hospital Italiano de Buenos Aires, Fundacion Dr. Pedro M. Catoggio para el Progreso de la Reumatología, Buenos Aires, Argentina. luis.catoggio@hospitalitaliano.org.ar, Soriano ER, Rosa JE |
| المصدر: | Reumatologia clinica [Reumatol Clin] 2009 Nov; Vol. 5 Suppl 3, pp. 35-9. Date of Electronic Publication: 2009 Sep 25. |
| نوع المنشور: | English Abstract; Journal Article |
| اللغة: | Spanish; Castilian |
| بيانات الدورية: | Publisher: Elsevier Doyma Country of Publication: Spain NLM ID: 101293923 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1885-1398 (Electronic) Linking ISSN: 1699258X NLM ISO Abbreviation: Reumatol Clin Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: <2009-> : Barcelona : Elsevier Doyma Original Publication: Barcelona : Doyma, c2005- |
| مستخلص: | Diagnosis should include mandatory muscle biopsy to identify inclusion body myositis. Most forms of inflammatory myopathies are still treated similarly, although treatment strategies remain empirical and controlled trials are few. Muscle strength and CPK levels remain the most frequently used measures to monitor disease activity and response to therapy. Corticosteroids are the main pillar of drug therapy but simultaneous use of corticosteroid-sparing drugs may be considered from the start. The most frequently used drugs for combined therapy are methotrexate, azathioprine and antimalarials in cases of dermatomyositis. In refractory cases, especially if life threatening, rituximab has appeared to be effective although there are no controlled trials, and there is some consensus that this should be used prior to Immunoglobulin. Anti TNF antibodies have not been useful in these diseases. Cyclosporin (especially with lung involvement) and Mofetil mycophenolate may also have a role in non responding cases. Treatment of inclusion body myositis remains unsatisfactory. (Copyright © 2009 Elsevier España, S.L. All rights reserved.) |
| تواريخ الأحداث: | Date Created: 20110729 Date Completed: 20120329 Latest Revision: 20110728 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.reuma.2009.07.004 |
| PMID: | 21794668 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1885-1398 |
|---|---|
| DOI: | 10.1016/j.reuma.2009.07.004 |